David Shaw’s Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share IBER.WS Stock Holding History

David Shaw’s Portfolio IBER.WS Stock Details IBER.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-40,932	Closed	-$729	–	5151
2022 Q4	$729	Hold	40,932	–	–	﹤0.01%	4801
2022 Q3	$3K	Hold	40,932	–	–	﹤0.01%	5078
2022 Q2	$3K	Hold	40,932	–	–	﹤0.01%	5263
2022 Q1	$8K	Hold	40,932	–	–	﹤0.01%	5434
2021 Q4	$22K	Hold	40,932	–	–	﹤0.01%	5292
2021 Q3	$24K	Buy	40,932 +28,432	+227%	+$19.1K	﹤0.01%	4884
2021 Q2	$10K	Buy	+12,500	New	+$7.59K	﹤0.01%	4718

Other funds holding IBER.WS

LCM

Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return

David Shaw's IBER.WS Position: Q1 2023 in Review

David Shaw sold out of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) in Q1 2023, closing a stake of 40,932 shares — an estimated $729 sold.

David Shaw first reported a position in IBER.WS in Q2 2021 and held it in 7 quarters. The position peaked at $24K in Q3 2021. 1 fund tracked by Wall St. Rank holds IBER.WS as of Q1 2023.

David Shaw reported no remaining Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position as of Q1 2023 after selling out during the quarter.
David Shaw sold 40,932 Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share shares in Q1 2023, an estimated $729.
David Shaw first reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in Q2 2021 and held it in 7 quarters.
David Shaw's Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position peaked at $24K in Q3 2021.
1 fund tracked by Wall St. Rank held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share as of Q1 2023.

Based on D.E. Shaw & Co's 13F filing for Q1 2023, filed 15 May 2023.